It is the second licensing deal involving siRNA between GSK and a Chinese biotech in the last few months, coming after the UK ...

Bayer has agreed terms for its first biopharma acquisition in years, paying $300 million upfront for privately-held US ...

While still making up a modest part of that total, oral Wegovy (semaglutide) performed better than expected since its launch ...

Navdeep "Navi" Chadha is co-founder and CTO of Axtria, a global provider of AI-powered data analytics and cloud software for ...

Cytokinetics' cardiac myosin inhibitor Myqorzo has succeeded where first-to-market Camzyos from Bristol Myers Squibb failed, ...

The team, led by scientists at VIB and KU Leuven in Belgium, have identified two types of Parkinson's – and five subtypes – ...

Europe is undergoing profound social, political, and technological transformation, with direct implications for mental health ...

In today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Boyang Wang, the founder of Immortal Dragons, ...

New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments, including GLP-1 agonist therapies. The shift from a ...

Cytospire Therapeutics was in the spotlight this morning after announcing an oversubscribed Series A to fund a new form of ...

Norgine's CEO Janneke van der Kamp has said other portfolio-boosting deals could be on the way. Netherlands-based pharma group Norgine has expanded its rare disease portfolio with the acquisition of ...

After failing to muster sufficient support for an IPO last year, autoimmune and inflammatory disease specialist Odyssey ...